Cybin Inc. Common Shares (CYBN)
9.0000
+0.6100 (7.27%)
NYSE · Last Trade: Jul 1st, 11:36 PM EDT
Detailed Quote
| Previous Close | 8.390 |
|---|---|
| Open | 8.920 |
| Bid | 8.940 |
| Ask | 9.110 |
| Day's Range | 8.750 - 9.830 |
| 52 Week Range | 4.810 - 13.88 |
| Volume | 1,153,557 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 326,838 |
Chart
About Cybin Inc. Common Shares (CYBN)
Cybin Inc is a biotechnology company focused on developing innovative psychedelic-based therapeutic solutions to address various mental health disorders. The company is engaged in research and clinical development of psychedelic compounds, aiming to enhance mental health treatment options through advanced drug formulations and delivery methods. By leveraging the potential of psychedelics, Cybin strives to provide patients with new avenues for healing and improved quality of life, while also working to advance the understanding and acceptance of psychedelic therapies in mainstream medicine. Read More
News & Press Releases
Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with High Trail Special Situations LLC (“High Trail”), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the “Convertible Debentures”). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the “Private Placement”). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties.
By Cybin Inc. · Via Business Wire · July 1, 2025
– Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Toronto – Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing […]
Via FinancialNewsMedia · July 1, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported audited financial results for its fiscal year ended March 31, 2025, and recent business highlights.
By Cybin Inc. · Via Business Wire · June 30, 2025
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END
Via FinancialNewsMedia · July 1, 2025
Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with High Trail Special Situations LLC (“High Trail”), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the “Convertible Debentures”). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the “Private Placement”). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties.
By Cybin Inc. · Via Business Wire · June 30, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
Cybin (NYSE American: CYBN) (NEO: CYBN) issued a corporate update emphasizing continued momentum in its clinical pipeline, including the advancement of its lead candidate CYB003 into Phase 3 development. CEO Doug Drysdale underscored the growing regulatory clarity around psychedelic therapeutics and expressed optimism that Cybin’s IP portfolio and clinical strategy position the company to help transform mental health treatment. Drysdale also noted favorable shifts in regulatory sentiment as a key tailwind for expediting the review process.
Via Investor Brand Network · June 13, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update.
By Cybin Inc. · Via Business Wire · June 13, 2025
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, scheduled for June 16–17, 2025. The company is advancing next-generation neuropsychiatric treatments aimed at transforming mental healthcare.
Via Investor Brand Network · June 12, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, taking place June 16-17, 2025.
By Cybin Inc. · Via Business Wire · June 12, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the Psychedelic Science 2025 Conference, held June 16–20 in Denver. Drysdale will participate in the panel “The Home Stretch: Pivotal Trials and Preparing for Launch” on Thursday, June 19 at 9:30 a.m. MDT. He emphasized the importance of collaborative dialogue in advancing psychedelic therapeutics, noting Cybin’s commitment to progressing clinical development and delivering next-generation mental health treatments.
Via Investor Brand Network · June 11, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the Psychedelic Science 2025 Conference taking place June 16-20, 2025 in Denver, Colorado. The details are as follows:
By Cybin Inc. · Via Business Wire · June 11, 2025
Federal support for psychedelics is rising fast. One biotech CEO explains what it means for clinical trials, access, and real-world therapy.
Via Benzinga · June 3, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company focused on next-generation mental health therapies, announced the issuance of U.S. patent 12,318,477 supporting its CYB004 program, a deuterated DMT candidate being developed for generalized anxiety disorder (“GAD”). The patent, which covers novel intramuscular formulations of DMT and related compounds, extends exclusivity through 2040. CEO Doug Drysdale highlighted the patent as further validation of CYB004’s potential to offer rapid-acting, short-duration treatment with patient-friendly delivery. The compound is currently in Phase 2 trials, expected to complete mid-2025. Cybin now holds more than 90 granted patents and over 230 pending applications.
Via Investor Brand Network · June 3, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder (“GAD”).
By Cybin Inc. · Via Business Wire · June 3, 2025
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
Via Benzinga · May 24, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a Water Tower Research Fireside Chat on May 29, 2025, at 11 a.m. ET. The discussion will cover Cybin’s CYB003 Phase 3 program, recent clinical partnerships, its collaboration with Thermo Fisher, and insights on the evolving regulatory landscape for psychedelics. The event will also explore Cybin’s strategy in interventional psychiatry and its alliance with Osmind.
Via Investor Brand Network · May 22, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a Water Tower Research Fireside Chat taking place on Thursday, May 29, 2025, at 11:00 a.m. ET.
By Cybin Inc. · Via Business Wire · May 22, 2025
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission to develop next-generation neuropsychiatric treatments. CYB003, a deuterated psilocin candidate, has received Breakthrough Therapy Designation, and early data show 100% response and 71% remission rates after two 16 mg doses. Cybin expects to launch the EMBRACE Phase 3 trial and complete its Phase 2 GAD study by mid-2025.
Via Investor Brand Network · May 20, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, applauds recent comments made by Dr. Martin Makary, Commissioner of the U.S. FDA relating to the importance of accelerating and prioritizing research on the clinical benefits of psychedelic therapeutics.
By Cybin Inc. · Via Business Wire · May 20, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production in Ohio. CYB003 received FDA Breakthrough Therapy Designation in March 2024, and its ongoing Phase 3 PARADIGM trial follows strong Phase 2 results showing a 100% response rate and 71% remission with two 16 mg doses.
Via Investor Brand Network · May 15, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has engaged Thermo Fisher Scientific (“Thermo Fisher”), the world leader in serving science, to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, the Company’s proprietary deuterated psilocin program in Phase 3 development for the adjunctive treatment of Major Depressive Disorder (“MDD”).
By Cybin Inc. · Via Business Wire · May 15, 2025
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The session will be webcast live at 1:40 p.m. ET and later available via the company’s investor relations site.
Via Investor Brand Network · May 14, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase, taking place May 21, 2025.
By Cybin Inc. · Via Business Wire · May 14, 2025
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced the issuance of U.S. patent 12,291,499 for its CYB003 program targeting major depressive disorder (MDD). The patent covers pharmaceutical compositions and oral dosage forms related to Cybin’s proprietary deuterated psilocin analog and offers exclusivity through 2041. The company is currently dosing patients in a Phase 3 trial and emphasized the importance of strong IP protection as it advances next-generation mental health therapies.
Via Investor Brand Network · May 8, 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD.
By Cybin Inc. · Via Business Wire · May 8, 2025